Last reviewed · How we verify
Hyruan Plus
Hyruan Plus is a viscoelastic hyaluronic acid-based injection that provides lubrication and cushioning to damaged joints.
Hyruan Plus is a viscoelastic hyaluronic acid-based injection that provides lubrication and cushioning to damaged joints. Used for Osteoarthritis of the knee.
At a glance
| Generic name | Hyruan Plus |
|---|---|
| Sponsor | LG Life Sciences |
| Drug class | Viscosupplement |
| Target | Hyaluronic acid receptor (CD44) |
| Modality | Small molecule |
| Therapeutic area | Orthopedics / Rheumatology |
| Phase | Phase 3 |
Mechanism of action
The drug is a viscosupplement containing hyaluronic acid, a naturally occurring polysaccharide found in synovial fluid. It works by restoring the viscoelastic properties of joint fluid, reducing friction between cartilage surfaces and providing shock absorption. This helps alleviate pain and improve joint mobility in osteoarthritis.
Approved indications
- Osteoarthritis of the knee
Common side effects
- Injection site pain or swelling
- Transient joint effusion
- Local inflammation
Key clinical trials
- Comparison of Single Intra-articular Injection of Hyruan-One With Hylan G-F 20 in Knee Osteoarthritis (PHASE4)
- Verification of the Efficacy/Safety of the Mixed Drug Injectable Delivery Vehicle for Treating Intractable Hearing Loss (PHASE1, PHASE2)
- Is Combined Steroid and Sodium Hyaluronate Hydrodilatation More Effective Than Isolated Steroid Hydrodilatation in Treating Patients With Adhesive Capsulitis (NA)
- The Efficacy of Ultrasound-guided Hydrodilatation With Hyaluronic Acid for Patients With Adhesive Capsulitis (NA)
- Effects of Knee Injections on Patients With Knee Osteoarthritis (PHASE4)
- Study to Evaluate the Efficacy and Safety of Intra-articular DA-5202 in Patients With Osteoarthritis of the Knee (PHASE2)
- Intraarticular Glucose Versus Hyaluronic Acid Injection for Knee Osteoarthrosis (NA)
- What Factors Are Associated With Prognosis of Rotator Cuff Disorder After Subacromial Hyaluronic Acid Injection (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Hyruan Plus CI brief — competitive landscape report
- Hyruan Plus updates RSS · CI watch RSS
- LG Life Sciences portfolio CI